IBA Doses First Patient in Head and Neck Cancer Proton Therapy Trial

MT Newswires · 2d ago
02:01 AM EDT, 10/21/2026 (MT Newswires) -- Ion Beam Applications (IBAB.BR), or IBA, dosed the first patient in its C-Flash-01 clinical trial evaluating ConformalFlash proton therapy for head and neck cancer patients requiring re-irradiation. The trial will assess the feasibility of delivering the therapy using Bragg peak proton beams at ultra-high dose rates, the Belgium-based particle accelerator technology company said Wednesday.